HUP0204417A2 - Oral ciprofloxacin-composition of controlled release - Google Patents

Oral ciprofloxacin-composition of controlled release

Info

Publication number
HUP0204417A2
HUP0204417A2 HU0204417A HUP0204417A HUP0204417A2 HU P0204417 A2 HUP0204417 A2 HU P0204417A2 HU 0204417 A HU0204417 A HU 0204417A HU P0204417 A HUP0204417 A HU P0204417A HU P0204417 A2 HUP0204417 A2 HU P0204417A2
Authority
HU
Hungary
Prior art keywords
controlled release
composition
weight
ciprofloxacin
oral
Prior art date
Application number
HU0204417A
Other languages
Hungarian (hu)
Inventor
Brij Khera
Gour Mukherji
Ashok Rampal
John N Staniforth
Naresh Talwar
Badri N Vishwanathan
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of HUP0204417A2 publication Critical patent/HUP0204417A2/en
Publication of HUP0204417A3 publication Critical patent/HUP0204417A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgya szabályozott hatóanyag leadására szolgáló, orális,napi egyszeri humán tablettakészítmény, amely hatóanyagkéntgyógyászatilag hatásos mennyiségű ciprofloxacint, valamintsegédanyagként 0,1-8,0 tömeg% viszkózussá tevő és/vagy gélesítőanyagot, 5,0-15 tömeg% gázképző anyagot és 3,0-15 tömeg% duzzadókomponenst tartalmaz. ÓThe subject of the invention is an oral, once-a-day human tablet preparation for the controlled release of an active ingredient, which contains a medicinally effective amount of ciprofloxacin as the active ingredient, as well as 0.1-8.0% by weight of a viscous and/or gelling agent, 5.0-15% by weight of a gas-forming agent and 3, Contains 0-15% swelling component by weight. HE

HU0204417A 2000-03-03 2001-02-28 Oral ciprofloxacin-composition of controlled release HUP0204417A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51788700A 2000-03-03 2000-03-03
PCT/IB2001/000279 WO2001064183A1 (en) 2000-03-03 2001-02-28 Orally administered controlled delivery system for once daily administration of ciprofloxacin

Publications (2)

Publication Number Publication Date
HUP0204417A2 true HUP0204417A2 (en) 2003-05-28
HUP0204417A3 HUP0204417A3 (en) 2005-03-29

Family

ID=24061635

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204417A HUP0204417A3 (en) 2000-03-03 2001-02-28 Oral ciprofloxacin-composition of controlled release

Country Status (31)

Country Link
EP (1) EP1263409A1 (en)
JP (1) JP2003525229A (en)
KR (1) KR20030009374A (en)
CN (1) CN1420763A (en)
AP (2) AP1485A (en)
AR (1) AR032614A1 (en)
AU (1) AU3589701A (en)
BG (1) BG107055A (en)
BR (1) BR0108958A (en)
CA (1) CA2400950A1 (en)
CZ (1) CZ20022883A3 (en)
DO (1) DOP2001000130A (en)
EA (1) EA200200914A1 (en)
EC (1) ECSP013952A (en)
EE (1) EE200200497A (en)
GT (1) GT200100033A (en)
HN (1) HN2001000038A (en)
HR (1) HRP20020715A2 (en)
HU (1) HUP0204417A3 (en)
IL (1) IL151553A0 (en)
IS (1) IS6532A (en)
MX (1) MXPA02008568A (en)
NO (1) NO20024108L (en)
NZ (1) NZ520927A (en)
OA (1) OA12381A (en)
PE (1) PE20011113A1 (en)
PL (1) PL365071A1 (en)
SK (1) SK12542002A3 (en)
WO (1) WO2001064183A1 (en)
YU (1) YU66202A (en)
ZA (1) ZA200206764B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20030229101A1 (en) * 2002-06-06 2003-12-11 Sherman Bernard Charles Tablets comprising ciprofloxacin hydrochloride
DE10351448A1 (en) 2003-11-04 2005-06-09 Bayer Healthcare Ag Flavor-containing drug formulations with improved pharmaceutical properties
DE602005007205D1 (en) 2005-07-19 2008-07-10 Ethypharm Sa Gastroretentive compositions and methods of preparation
DE602006012962D1 (en) * 2006-07-19 2010-04-29 Tabuk Pharmaceutical Mfg Co Pharmaceutical preparations of ciprofloxacin
WO2016115253A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Ofcolordo, A Body Corporate Insulin mimotopes and methods of using the same
CA3015400A1 (en) * 2016-02-23 2017-08-31 Matripharm International Inc. Dual-rate release formulation with high drug loading
CA3018727C (en) 2016-03-24 2024-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating autoimmune disease
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN109806237A (en) * 2019-03-13 2019-05-28 悦康药业集团上海制药有限公司 A kind of Ciprofloxacin Lactate effervescent tablet and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (en) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk Medice release solid pharmaceutical preparation of gastric suspending type sustained
DE4406424A1 (en) * 1994-02-28 1995-08-31 Bayer Ag Expandable dosage forms
DE19839057A1 (en) * 1998-08-28 2000-03-02 Koch Berthold Purge air controller for a drying device for compressed air
EE200100153A (en) * 1998-09-14 2002-06-17 Ranbaxy Laboratories Limited Controlled drug delivery system for oral drug delivery that provides temporal and spatial control

Also Published As

Publication number Publication date
ECSP013952A (en) 2002-04-23
AP2002002627A0 (en) 2002-09-30
NO20024108L (en) 2002-10-25
GT200100033A (en) 2001-10-25
AP2001002084A0 (en) 2001-03-31
IL151553A0 (en) 2003-04-10
DOP2001000130A (en) 2004-03-31
CN1420763A (en) 2003-05-28
AP1485A (en) 2005-10-31
HUP0204417A3 (en) 2005-03-29
CA2400950A1 (en) 2001-09-07
BR0108958A (en) 2003-09-30
AR032614A1 (en) 2003-11-19
HN2001000038A (en) 2005-03-23
JP2003525229A (en) 2003-08-26
MXPA02008568A (en) 2003-02-24
CZ20022883A3 (en) 2003-04-16
KR20030009374A (en) 2003-01-29
NO20024108D0 (en) 2002-08-28
IS6532A (en) 2002-08-28
WO2001064183A1 (en) 2001-09-07
AU3589701A (en) 2001-09-12
NZ520927A (en) 2003-06-30
HRP20020715A2 (en) 2004-12-31
EA200200914A1 (en) 2003-02-27
BG107055A (en) 2003-06-30
YU66202A (en) 2005-09-19
SK12542002A3 (en) 2003-05-02
PL365071A1 (en) 2004-12-27
PE20011113A1 (en) 2001-10-14
EE200200497A (en) 2004-02-16
EP1263409A1 (en) 2002-12-11
OA12381A (en) 2004-09-06
ZA200206764B (en) 2003-03-04

Similar Documents

Publication Publication Date Title
MX339071B (en) Pregelatinized starch in a controlled release formulation.
HRP20030951B1 (en) Once-a-day oxycodone formulations
HUP0401314A2 (en) Breath freshening film
PT1401501E (en) ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF THE ACTIVE INGREDIENT
HUP0002935A2 (en) Gastroretentive controlled release microspheres for improved drug delivery
HUP0203028A2 (en) Pharmaceutical formulation containing tolterodine and its use
HUP0203176A2 (en) Solid, oral pharmaceutical composition containing simethicone
ES2157881T3 (en) PAROXETINE METHANOSULFONATE.
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
EP0966966A3 (en) Nefazodone dosage form
BG108516A (en) Pharmaceutical formulation
HUP0204417A2 (en) Oral ciprofloxacin-composition of controlled release
SE0300831D0 (en) New formulations and use therof
DE50005529D1 (en) ORAL PHARMACEUTICAL FORMS FOR ADMINISTRATING A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
ATE287264T1 (en) ORAL MEDICINAL PRODUCTS CONTAINING BUPRENORPHINE
HUP0104647A2 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
MXPA03008420A (en) Solid orally-dispersible pharmaceutical formulation.
ATE464878T1 (en) PHARMACEUTICAL COMPOSITION FOR NASAL USE OF FENTANYL
GB2420720A (en) Orthodontic brace
TW200616950A (en) Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (yc-1) as anti-platelet agents
AU2001252225A1 (en) Oral composition comprising chlorhexinine and maltitol or erythritol or a mixture thereof
DE60202590D1 (en) 2H-1-BENZOPYRANE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
DE60320039D1 (en) TRAMADOL FORMULATIONS WITH DELAYED RELEASE AND 24 HOUR EFFICACY
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
HUP0202324A2 (en) Prucalopride oral solution

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: RANBAXY LABORATORIES LIMITED, IN

Free format text: FORMER OWNER(S): RANBAXY LABORATORIES LIMITED, IN; RANBAXY LABORATORIES LIMITED, IN

FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): DR. ASBOTH DOMOKOS, DR, ASBOTH. DR. BICZI & TARSA UEGYVEDI ES SZABADALMI IRODA, HU

Representative=s name: MESTER TAMAS, SWORKS NEMZETKOEZI SZABADALMI UE, HU

FH92 Termination of representative

Representative=s name: DR. ASBOTH DOMOKOS, DR, ASBOTH. DR. BICZI & TA, HU